GlobeNewswire - Industry News on Biotechnology http://www.yebxqs.cn/RssFeed/industry/4573-Biotechnology/feedTitle/GlobeNewswire%20-%20Industry%20News%20on%20Biotechnology Contains the last 20 releases newsdesk@globenewswire.com (NewsDesk) Fri, 26 Feb 2021 21:15:00 GMT webmaster@globenewswire.com (Webmaster) http://www.yebxqs.cn/news-release/2021/02/26/2183715/0/en/NextCure-to-Host-Virtual-R-D-Update-Event-on-March-4-2021.html http://www.yebxqs.cn/news-release/2021/02/26/2183715/0/en/NextCure-to-Host-Virtual-R-D-Update-Event-on-March-4-2021.html Nasdaq:NXTC US65343E1082 NextCure to Host Virtual R&D Update Event on March 4, 2021 BELTSVILLE, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will host a Virtual R&D Update Event at 5:00 p.m. ET on Thursday, March 4.

]]>
Fri, 26 Feb 2021 21:15 GMT 2183715 en GlobeNewswire Inc. NextCure Fri, 26 Feb 2021 21:15 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/02/26/2183710/0/en/Transactions-with-shares-and-linked-securities-in-Genmab-A-S-made-by-managerial-employees-and-their-closely-associated-persons.html http://www.yebxqs.cn/news-release/2021/02/26/2183710/0/en/Transactions-with-shares-and-linked-securities-in-Genmab-A-S-made-by-managerial-employees-and-their-closely-associated-persons.html Copenhagen:GEN LSE:0MGB DK0010272202 Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons Company Announcement

]]>
Fri, 26 Feb 2021 21:12 GMT 2183710 en GlobeNewswire Inc. Genmab A/S Fri, 26 Feb 2021 21:12 GMT Insider's Buy/Sell European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/26/2183709/0/en/GENFIT-Revenues-and-Cash-Position-as-of-December-31-2020.html http://www.yebxqs.cn/news-release/2021/02/26/2183709/0/en/GENFIT-Revenues-and-Cash-Position-as-of-December-31-2020.html Paris:GNFT FR0004163111 GENFIT: Revenues and Cash Position as of December 31, 2020 Lille, France; Cambridge, MA; February 26, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced its cash position as of December 31, 2020 and revenues for 20202.

]]>
Fri, 26 Feb 2021 21:10 GMT 2183709 en GlobeNewswire Inc. GENFIT S.A. Fri, 26 Feb 2021 21:10 GMT Other News European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/26/2183709/0/fr/GENFIT-Chiffres-d-Affaires-et-Position-de-Tr%C3%A9sorerie-au-31-d%C3%A9cembre-2020.html http://www.yebxqs.cn/news-release/2021/02/26/2183709/0/fr/GENFIT-Chiffres-d-Affaires-et-Position-de-Tr%C3%A9sorerie-au-31-d%C3%A9cembre-2020.html Paris:GNFT FR0004163111 GENFIT : Chiffres d’Affaires et Position de Trésorerie au 31 décembre 2020 Lille (France), Cambridge (Massachusetts, états-Unis), le 26 février 2021 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de phase avancée engagée dans l’amélioration de la vie des patients atteints de maladies hépatiques et métaboliques, annonce aujourd’hui la position de sa trésorerie au 31 décembre 2020 et son chiffre d’affaires pour l’année 20202.

]]>
Fri, 26 Feb 2021 21:10 GMT 2183709 fr GlobeNewswire Inc. GENFIT S.A. Fri, 26 Feb 2021 21:10 GMT Other News European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/26/2183705/0/en/Grant-of-Restricted-Stock-Units-to-Management-and-Employees-and-Grant-of-Warrants-to-Employees-in-Genmab.html http://www.yebxqs.cn/news-release/2021/02/26/2183705/0/en/Grant-of-Restricted-Stock-Units-to-Management-and-Employees-and-Grant-of-Warrants-to-Employees-in-Genmab.html Copenhagen:GEN LSE:0MGB DK0010272202 Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab Company Announcement

]]>
Fri, 26 Feb 2021 21:08 GMT 2183705 en GlobeNewswire Inc. Genmab A/S Fri, 26 Feb 2021 21:09 GMT Regulatory information European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/26/2183700/0/en/Pacific-Biosciences-of-California-Inc-to-Present-at-Upcoming-Investor-Conferences.html http://www.yebxqs.cn/news-release/2021/02/26/2183700/0/en/Pacific-Biosciences-of-California-Inc-to-Present-at-Upcoming-Investor-Conferences.html Nasdaq:PACB US69404D1081 Pacific Biosciences of California, Inc. to Present at Upcoming Investor Conferences MENLO PARK, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) announced today that its executives will be speaking at the following investor conferences:

]]>
Fri, 26 Feb 2021 21:04 GMT 2183700 en GlobeNewswire Inc. Pacific Biosciences of California, Inc. Fri, 26 Feb 2021 21:04 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/02/26/2183695/0/en/Orphazyme-announces-participation-in-upcoming-virtual-investor-conferences.html http://www.yebxqs.cn/news-release/2021/02/26/2183695/0/en/Orphazyme-announces-participation-in-upcoming-virtual-investor-conferences.html Copenhagen:ORPHA DK0060910917 Orphazyme announces participation in upcoming?virtual investor conferences Orphazyme A/S
Investor news? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?

No. 04/2021???????????????????????????????????????????????????????????????????????????????????????????????????????????
Company Registration No. 32266355

]]>
Fri, 26 Feb 2021 20:38 GMT 2183695 en GlobeNewswire Inc. ORPHAZYME A/S Fri, 26 Feb 2021 20:39 GMT Other News European Regulatory News
http://www.yebxqs.cn/news-release/2021/02/26/2183649/0/en/U-S-Government-to-Purchase-Minimum-of-100-000-Doses-of-Etesevimab-and-Bamlanivimab-Neutralizing-Antibody-Therapy.html http://www.yebxqs.cn/news-release/2021/02/26/2183649/0/en/U-S-Government-to-Purchase-Minimum-of-100-000-Doses-of-Etesevimab-and-Bamlanivimab-Neutralizing-Antibody-Therapy.html HKSE:1877.HK Shenzhen:688180.SS CNE100003FF7 U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy SHANGHAI, China, Feb. 27, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced today that the U.S. government has agreed to purchase a minimum of 100,000 doses of etesevimab (JS016 or LY-CoV016) 1400 mg and bamlanivimab (LY-CoV555) 700 mg together, according to the company’s global partner Eli Lilly and Company (NYSE: LLY). Etesevimab and bamlanivimab together recently received emergency use authorization for the treatment of recently diagnosed, mild to moderate COVID-19 in patients who are at high risk of progressing to severe COVID-19 and/or hospitalization. Additionally, the National Institutes of Health (NIH) recently updated the COVID-19 Treatment Guidelines to recommend the use of bamlanivimab plus etesevimab for the treatment of outpatients with mild to moderate COVID-19 who are at high risk of clinical progression.

]]>
Fri, 26 Feb 2021 17:35 GMT 2183649 en GlobeNewswire Inc. Junshi Biosciences Fri, 26 Feb 2021 17:35 GMT Business Contracts Health Product / Services Announcement
http://www.yebxqs.cn/news-release/2021/02/26/2183540/0/en/UPDATE-Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Planned-Completion-and-Emergency-Use-Authorization-Request.html http://www.yebxqs.cn/news-release/2021/02/26/2183540/0/en/UPDATE-Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Planned-Completion-and-Emergency-Use-Authorization-Request.html CNSX:RVV.CN CNSX:RVV Other OTC:RVVTF Frankfurt:31R CA7615161030 UPDATE -- Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion?and Emergency Use Authorization Request TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

]]>
Fri, 26 Feb 2021 14:50 GMT 2183540 en GlobeNewswire Inc. Revive Therapeutics Ltd. Fri, 26 Feb 2021 14:50 GMT Health
http://www.yebxqs.cn/news-release/2021/02/26/2183487/0/en/Innovation-Pharma-Provides-Study-Details-for-Ongoing-Phase-2-Clinical-Trial-of-Brilacidin-in-Hospitalized-COVID-19-Patients.html http://www.yebxqs.cn/news-release/2021/02/26/2183487/0/en/Innovation-Pharma-Provides-Study-Details-for-Ongoing-Phase-2-Clinical-Trial-of-Brilacidin-in-Hospitalized-COVID-19-Patients.html Other OTC:IPIX US45782D1000 Innovation Pharma Provides Study Details for Ongoing Phase 2 Clinical Trial of Brilacidin in Hospitalized COVID-19 Patients WAKEFIELD, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides additional study details for its ongoing Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. Patients are being treated, with recruitment and enrollment progressing at trial sites.

]]>
Fri, 26 Feb 2021 14:00 GMT 2183487 en GlobeNewswire Inc. Innovation Pharmaceuticals Inc. Fri, 26 Feb 2021 14:01 GMT Product / Services Announcement Research Analysis and Reports clinical trials SARS-CoV-2 strains COVID-19
http://www.yebxqs.cn/news-release/2021/02/26/2183449/0/en/Peter-Lougheed-Centre-Joins-the-Phase-II-Trial-of-LSALT-Peptide-for-the-Treatment-of-Complications-in-Hospitalized-COVID-19-Patients.html http://www.yebxqs.cn/news-release/2021/02/26/2183449/0/en/Peter-Lougheed-Centre-Joins-the-Phase-II-Trial-of-LSALT-Peptide-for-the-Treatment-of-Complications-in-Hospitalized-COVID-19-Patients.html TSX-V:ARCH Other OTC:ACHFF CA03938C1041 Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary, Alberta has joined the Phase II trial of its lead drug LSALT peptide (Metablok), targeting the prevention of acute lung injury, acute kidney injury, and other complications caused by inflammation in hospitalized patients with moderate to severe cases of COVID-19.

]]>
Fri, 26 Feb 2021 13:42 GMT 2183449 en GlobeNewswire Inc. Arch Biopartners Fri, 26 Feb 2021 13:43 GMT Health Research Analysis and Reports prevent organ inflammation acute kidney injury ARDS Foundation covid-19 fda phase II trial Metablok prevent ICU admission
http://www.yebxqs.cn/news-release/2021/02/26/2183438/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Planned-Completion-and-Emergency-Use-Authorization-Request.html http://www.yebxqs.cn/news-release/2021/02/26/2183438/0/en/Revive-Therapeutics-Provides-Update-on-FDA-Phase-3-Clinical-Trial-for-Bucillamine-in-COVID-19-with-Planned-Completion-and-Emergency-Use-Authorization-Request.html CNSX:RVV.CN CNSX:RVV Other OTC:RVVTF Frankfurt:31R CA7615161030 Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

]]>
Fri, 26 Feb 2021 13:33 GMT 2183438 en GlobeNewswire Inc. Revive Therapeutics Ltd. Fri, 26 Feb 2021 13:33 GMT Health
http://www.yebxqs.cn/news-release/2021/02/26/2183418/0/en/Novavax-and-Takeda-Finalize-License-Agreement-for-Novavax-COVID-19-Vaccine-Candidate-in-Japan-Takeda-Initiates-Phase-1-2-Trial-in-Japan.html http://www.yebxqs.cn/news-release/2021/02/26/2183418/0/en/Novavax-and-Takeda-Finalize-License-Agreement-for-Novavax-COVID-19-Vaccine-Candidate-in-Japan-Takeda-Initiates-Phase-1-2-Trial-in-Japan.html Nasdaq:NVAX US6700021040 Novavax and Takeda Finalize License Agreement for Novavax’ COVID-19 Vaccine Candidate in Japan; Takeda?Initiates Phase 1/2 Trial in Japan GAITHERSBURG, Md., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced progress in its collaboration with Takeda Pharmaceutical Company Limited, originally announced in August. The companies have signed an exclusive license agreement for Takeda’s development, manufacturing and commercialization of NVX-CoV2373, Novavax’ COVID-19 vaccine candidate, in Japan. Additionally, Takeda dosed the first participants in a Phase 2 clinical trial to test the immunogenicity and safety of Novavax’ vaccine candidate in the Japanese population.

]]>
Fri, 26 Feb 2021 13:23 GMT 2183418 en GlobeNewswire Inc. Novavax, Inc. Fri, 26 Feb 2021 13:23 GMT Company Announcement Health Licensing Agreements covid-19 vaccine trial japan
http://www.yebxqs.cn/news-release/2021/02/26/2183373/0/en/Fortress-Biotech-Joins-Global-Movement-to-Raise-Awareness-for-Rare-Diseases-and-Supports-Rare-Disease-Day.html http://www.yebxqs.cn/news-release/2021/02/26/2183373/0/en/Fortress-Biotech-Joins-Global-Movement-to-Raise-Awareness-for-Rare-Diseases-and-Supports-Rare-Disease-Day.html Nasdaq:FBIO US34960Q1094 Fortress Biotech Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day? NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced its support for Rare Disease Day? on February 28, an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face.

]]>
Fri, 26 Feb 2021 13:00 GMT 2183373 en GlobeNewswire Inc. Fortress Biotech, Inc. Fri, 26 Feb 2021 13:00 GMT Calendar of Events Health Rare Disease Day
http://www.yebxqs.cn/news-release/2021/02/26/2183376/0/en/Mustang-Bio-Joins-Global-Movement-to-Raise-Awareness-for-Rare-Diseases-and-Supports-Rare-Disease-Day.html http://www.yebxqs.cn/news-release/2021/02/26/2183376/0/en/Mustang-Bio-Joins-Global-Movement-to-Raise-Awareness-for-Rare-Diseases-and-Supports-Rare-Disease-Day.html Nasdaq:MBIO US62818Q1040 Mustang Bio Joins Global Movement to Raise Awareness for Rare Diseases and Supports Rare Disease Day? WORCESTER, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced its support for Rare Disease Day? which takes place on February 28 and is an annual awareness day dedicated to elevating public understanding of rare diseases and calling attention to the special challenges people living with rare diseases face.

]]>
Fri, 26 Feb 2021 13:00 GMT 2183376 en GlobeNewswire Inc. Mustang Bio, Inc. Fri, 26 Feb 2021 13:00 GMT Calendar of Events Health rare disease day
http://www.yebxqs.cn/news-release/2021/02/26/2183399/0/en/ADMA-Biologics-Presents-Late-Breaking-Poster-Presentation-Highlighting-Clinical-Utility-of-S-Pneumoniae-Hyperimmune-Globulin-at-the-2021-American-Academy-of-Allergy-Asthma-Immunolo.html http://www.yebxqs.cn/news-release/2021/02/26/2183399/0/en/ADMA-Biologics-Presents-Late-Breaking-Poster-Presentation-Highlighting-Clinical-Utility-of-S-Pneumoniae-Hyperimmune-Globulin-at-the-2021-American-Academy-of-Allergy-Asthma-Immunolo.html Nasdaq:ADMA US0008991046 ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple Serotypes

]]>
Fri, 26 Feb 2021 13:00 GMT 2183399 en GlobeNewswire Inc. ADMA Biologics, Inc. Fri, 26 Feb 2021 13:02 GMT Calendar of Events Health Trade Show
http://www.yebxqs.cn/news-release/2021/02/26/2183338/0/en/SIGA-Technologies-to-Host-Business-Update-Call-on-March-4-2021-Following-Release-of-Year-End-2020-Financial-Results.html http://www.yebxqs.cn/news-release/2021/02/26/2183338/0/en/SIGA-Technologies-to-Host-Business-Update-Call-on-March-4-2021-Following-Release-of-Year-End-2020-Financial-Results.html Nasdaq:SIGA US8269171067 SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, March 4, 2021. Participating on the call will be Dr. Phil Gomez, Chief Executive Officer, Daniel Luckshire, Chief Financial Officer, and Dr. Dennis Hruby, Chief Scientific Officer.

]]>
Fri, 26 Feb 2021 12:30 GMT 2183338 en GlobeNewswire Inc. SIGA Technologies Inc. Fri, 26 Feb 2021 12:30 GMT Calendar of Events
http://www.yebxqs.cn/news-release/2021/02/26/2183345/0/en/TG-Therapeutics-to-Host-Conference-Call-on-Fourth-Quarter-and-Year-End-2020-Financial-Results-and-Business-Update.html http://www.yebxqs.cn/news-release/2021/02/26/2183345/0/en/TG-Therapeutics-to-Host-Conference-Call-on-Fourth-Quarter-and-Year-End-2020-Financial-Results-and-Business-Update.html Nasdaq:TGTX US88322Q1085 TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2020 Financial Results and Business Update Conference call to be held Tuesday, March 2, 2021 at 8:30 AM ET]]> Fri, 26 Feb 2021 12:30 GMT 2183345 en GlobeNewswire Inc. TG Therapeutics, Inc. Fri, 26 Feb 2021 12:31 GMT Calendar of Events http://www.yebxqs.cn/news-release/2021/02/26/2183285/0/en/Silence-Therapeutics-and-Mallinckrodt-Initiate-Work-on-Third-Target-as-Part-of-Ongoing-RNAi-Research-Collaboration-for-Complement-Mediated-Diseases.html http://www.yebxqs.cn/news-release/2021/02/26/2183285/0/en/Silence-Therapeutics-and-Mallinckrodt-Initiate-Work-on-Third-Target-as-Part-of-Ongoing-RNAi-Research-Collaboration-for-Complement-Mediated-Diseases.html LSE:SLN Nasdaq:NASDAQ: SLN GB00B9GTXM62 Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases Silence Therapeutics and Mallinckrodt Initiate Work on Third Target as Part of Ongoing RNAi Research Collaboration for Complement-Mediated Diseases

]]>
Fri, 26 Feb 2021 12:00 GMT 2183285 en GlobeNewswire Inc. Silence Therapeutics plc Fri, 26 Feb 2021 12:00 GMT Press releases Company Announcement
http://www.yebxqs.cn/news-release/2021/02/26/2183125/0/sv/Antal-aktier-och-r%C3%B6ster-i-Active-Biotech.html http://www.yebxqs.cn/news-release/2021/02/26/2183125/0/sv/Antal-aktier-och-r%C3%B6ster-i-Active-Biotech.html Stockholm:ACTI SE0001137985 9054 MyWeb Antal aktier och r?ster i Active Biotech Antalet aktier och r?ster i Active Biotech har f?r?ndrats p? grund av den nyligen genomf?rda f?retr?desemissionen.

]]>
Fri, 26 Feb 2021 07:30 GMT 2183125 sv GlobeNewswire Inc. Active Biotech Fri, 26 Feb 2021 07:30 GMT Changes in company's own shares European Regulatory News
粉色午夜视频/色戒未删减版在线观看视频/44383x3全国最大的免费观看/冲田杏梨番号